Rabeto plus: a valuable drug for managing functional dyspepsia.

Simple item page
dc.contributor.authorGhosh, Asimen_US
dc.contributor.authorHalder, Susantaen_US
dc.contributor.authorMandal, Sanjoyen_US
dc.contributor.authorMandal, Arpanen_US
dc.contributor.authorBasu, Mitalien_US
dc.contributor.authorDabholkar, Pareenen_US
dc.date.accessioned2008-11-17en_US
dc.date.accessioned2009-05-31T11:29:53Z
dc.date.available2008-11-17en_US
dc.date.available2009-05-31T11:29:53Z
dc.date.issued2008-11-17en_US
dc.description.abstractThe aim of the study was to evaluate and document the efficacy and tolerability of rabeto plus (FDC of rabeprazole and itopride) in management of functional dyspepsia. It was an open, prospective, non-comparative, multidose study. The patients with functional dyspepsia (NERD or non-erosive reflux disease) attending OPD of a leading, tertiary care, teaching hospital in West Bengal (BS Medical College, Bankura) were inducted in the study. A total of 46 adult patients of either sex with functional dyspepsia and a clinical diagnosis of NERD were given 1 capsule of rabeto plus before breakfast, for up to 4 weeks. Primary efficacy variables were relief from symptoms of heartburn, nausea, vomiting, waterbrash and fullness. Secondary efficacy variables were global assessment of efficacy and toleration by patients and treating physicians. The tolerability was assessed on the basis of record of spontaneously reported adverse events with their nature, intensity and outcome. Out of 55 patients enrolled in the study, 46 completed the study as planned, while 9 patients were lost to follow-up (dropped). Most patients reported near total symptom relief by the end of study. Total symptom score showed remarkable and significant improvement from baseline to end of the study. Importantly, none of the patients reported any side-effect. All participants tolerated the drug well. Moreover, response to study drug was rated as excellent or good by over 93% patients and their treating physicians. This means that 9 out 10 patients receiving rabeto plus reported desired symptom relief from dyspepsia. Thus it was concluded that rabeto plus is a valuable drug for treatment of functional dyspepsia or NERD.en_US
dc.description.affiliationDepartment of Pharmacology, BS Medical College, Bankura.en_US
dc.identifier.citationGhosh A, Halder S, Mandal S, Mandal A, Basu M, Dabholkar P. Rabeto plus: a valuable drug for managing functional dyspepsia. Journal of the Indian Medical Association. 2008 Nov; 106(11): 752-4en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/100281
dc.language.isoengen_US
dc.source.urihttps://www.jimaonline.org.in/en_US
dc.subject.mesh2-Pyridinylmethylsulfinylbenzimidazoles --therapeutic useen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshBenzamides --therapeutic useen_US
dc.subject.meshBenzyl Compounds --therapeutic useen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshDyspepsia --complicationsen_US
dc.subject.meshFemaleen_US
dc.subject.meshGastroesophageal Reflux --complicationsen_US
dc.subject.meshGastrointestinal Agents --therapeutic useen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshProton Pump Inhibitors --therapeutic useen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshYoung Adulten_US
dc.titleRabeto plus: a valuable drug for managing functional dyspepsia.en_US
dc.typeClinical Trialen_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Indian Medical Association